Novo Nordisk A/S vs Zscaler Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Zscaler Inc trades at $148.21 (market cap $24.23B). The key difference: Novo Nordisk A/S is far larger — about 9.1× Zscaler Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| NVO | ZS | |
|---|---|---|
Market Cap | $220.53B | $24.23B |
Sector | Health | Technology |
52-Week High | $71.70 | $336.27 |
52-Week Low | $35.29 | $118.05 |
Enterprise Value | $239.49B | $22.55B |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →